Keros Therapeutics, Inc.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts. The company focuses on the discovery, development, and commercialization of novel treatments for patients suffering from disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. Keros aims to bring meaningful therapeutic advances to patients and their families by developing safe, disease-modifying drugs for serious and rare diseases with high unmet medical needs.

Keros Therapeutics' pipeline includes several product candidates. Rinvatercept (KER-065) is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), with a Phase 2 clinical trial for DMD expected to begin in the second quarter of 2026. Elritercept (KER-050), the company's most advanced product candidate, targets low blood cell counts (cytopenias) in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF). Takeda Pharmaceuticals holds an exclusive global license for elritercept, with plans to advance it into a Phase 3 clinical trial for first-line MDS. Another candidate, KER-047, is in Phase 1 clinical trials for anemia.

In a significant development in May 2025, Keros Therapeutics discontinued the development of cibotercept (KER-012) for pulmonary arterial hypertension due to safety concerns and a lack of clinically meaningful efficacy, leading to a 45% reduction in its workforce. The company has since strategically realigned its resources to prioritize rinvatercept (KER-065). Jasbir S. Seehra, Ph.D., serves as the President, CEO, Treasurer, and Director, having held the CEO position since December 2015. Keros also completed a $375 million capital return program in late 2025.